Qurient Co

Qurient Co P/B

The P/B (Price-to-Book Ratio) of Qurient Co (115180.KQ) as of Oct 26, 2026 is 37.69. In the previous year, P/B (Price-to-Book Ratio) was 22.27 — a change of 69.20% (higher).

P/B

37.69

YoY

69.20%

Last updated:

P/B (Price-to-Book Ratio) of Qurient Co is 2025 37.69 . P/B (Price-to-Book Ratio) of Qurient Co was 2024 22.27 . It decreases by 69.20% higher compared to the previous year.

The Qurient Co P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
32.56 KRW
Jan 1, 2019
73.82 KRW
Jan 1, 2020
22.68 KRW
Jan 1, 2021
24.87 KRW
Jan 1, 2022
41.45 KRW
Jan 1, 2023
27.52 KRW
Jan 1, 2024
22.27 KRW
Jan 1, 2025
37.69 KRW
The Qurient Co P/B history
YEARP/BYoY
37.69+69.20%
22.27-19.06%
27.52-33.60%
41.45+66.68%
24.87+9.64%
22.68-69.28%
73.82+126.75%
32.56-63.12%
88.28+67.55%
52.69-88.11%
443.31-849.25%
-59.17—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Qurient Co Stock analysis

What does Qurient Co do? Qurient Co., Ltd. develops novel therapeutics with two main program phases. The development phase includes Q203 for drug-resistant tuberculosis, Q301 for atopic dermatitis, and Q701 for drug-resistant cancer and anti-cancer immunotherapy. The research phase focuses on five lipoxygenase (5LO) inhibitor asthma medicines and a cyclin dependent kinase 7 (CDK7) inhibitor cancer drug. The company generates revenue through these therapeutic programs, targeting pharmaceutical companies and healthcare providers seeking innovative treatments for resistant diseases and chronic conditions. Qurient's products are developed for specific medical needs, with Q203 addressing tuberculosis that resists standard drugs, Q301 treating skin inflammation conditions, and Q701 enhancing cancer immunotherapy. The research phase programs aim to advance asthma and cancer treatments through novel inhibitors. Pharmaceutical companies and healthcare providers purchase these therapies to address unmet medical needs in their markets. The company's revenue streams come from the development and potential commercialization of Q203, Q301, Q701, and the research phase programs. These programs target segments including tuberculosis treatment, dermatology, oncology, and respiratory diseases. Pharmaceutical firms and healthcare institutions are the primary buyers of Qurient's therapeutic solutions for drug-resistant conditions and advanced treatment options. Qurient Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Qurient Co stock

P/B (Price-to-Book Ratio) of Qurient Co is 37.69 in 2025.

P/B (Price-to-Book Ratio) of Qurient Co changed from 22.27 to 37.69, representing a 69.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Qurient Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Qurient Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Qurient Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Qurient Co